Acurx Pharmaceuticals, Inc.

Stage 4 · Declining · week 22

As of Oct 22, 2026, Acurx Pharmaceuticals is in Stage 4, the downtrend phase, now in week 22 (since May 22, 2026). It closed at $1.14, 82.8% below its 52-week high and below its 200-day average, which is falling.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. More about the company

$1.14

-0.87% today

$6.3M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ACXP early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 45w

S4 15w

S4 22w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 8w → S1 3w → S2 9w → S3 12w → S4 10w → S1 8w → S4 45w → S1 7w → S4 12w → S1 6w → S4 15w → S1 8w → S4 22w current

Total tracked: 166 weeks across 13 stage runs.

ACXP among Biotechnology485th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…485	ACXPAcurx Pharmaceuticals, Inc.	Stage 4 · wk 22	10	−16.8%

vs 52W High

-82.8%

$1.10 lo$6.63 hi

82.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 22

1w13w26w

Week 22, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-43.8%

200 DMA: $2.03 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.20x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-16.8%

-19.7%

-43.3%

YTD

-58.7%

-83.7%

Scan Membership

Breakout Watch

Latest: 2023-11-08

3 appearances in last 60 days. First seen: 2022-09-09.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 22 · Vol 0.20x

2026-10-21S4

Wk 21 · Vol 0.15x

2026-10-20S4

Wk 21 · Vol 0.50x

2026-10-19S4

Wk 21 · Vol 0.38x

2026-10-16S4

Wk 21 · Vol 1.24x

2026-10-15S4

Wk 21 · Vol 0.74x

2026-10-14S4

Wk 20 · Vol 0.61x

2026-10-13S4

Wk 20 · Vol 0.73x

2026-10-12S4

Wk 20 · Vol 0.61x

2026-10-09S4

Wk 20 · Vol 0.30x

2026-10-08S4

Wk 20 · Vol 0.55x

2026-10-07S4

Wk 19 · Vol 0.58x

Moving averages & range

50 DMA

$1.34

200 DMA

$2.03

52W High

$6.63

52W Low

$1.10

5D Low

$1.10

Resistance levels (recent highs)

20d High

$1.36

60d High

$1.65

120d High

$2.18

250d High

$6.63

Next resistance

+19.3%

to 20d High

ROE

-128.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.7

Acurx Pharmaceuticals: quick answers

What stage is Acurx Pharmaceuticals in?

As of Oct 22, 2026, Acurx Pharmaceuticals (ACXP) is in Stage 4, the downtrend phase. It entered Stage 4 on May 22, 2026 and is in week 22. What the four stages mean

Is Acurx Pharmaceuticals in an uptrend?

No. Acurx Pharmaceuticals is in a Stage 4 downtrend. It trades 43.8% below its 200-day average, which is falling.

How far is Acurx Pharmaceuticals from its 52-week high?

Acurx Pharmaceuticals closed at $1.14 on Oct 22, 2026, 82.8% below its 52-week high of $6.63. Its 52-week low is $1.10.

How has Acurx Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Acurx Pharmaceuticals is down 83.7% over the past year and down 58.7% so far in 2026.

Which sector and industry is Acurx Pharmaceuticals in?

Acurx Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.